Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is April 24, 2025, covering share purchases executed on April 23, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing share buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics
The filing details specific metrics related to the share repurchase activity rather than operational financial performance (revenue, profit, or cash flow are not reported in this document).
- Shares Purchased (April 23, 2025): 715,130 ordinary shares.
- Price Range: Lowest price paid was 1,361.50 GBp; highest price paid was 1,388.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,380.02 GBp.
- Total Buyback Volume (Since Feb 24, 2025): 32,012,052 ordinary shares.
- Treasury Shares Held: 201,082,355 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,114,156,103 ordinary shares.
- Total Voting Rights: 4,114,156,103.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares following the April 23 transaction. The filing does not provide comparative financial data (e.g., year-over-year revenue or profit changes) as it is a transactional report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the GSK 2024 Annual Report on Form 20-F (pages 277 to 285). The purchased shares are to be held as Treasury shares.
Investor Verification Checklist
- Verify the total number of shares in issue (4,114,156,103) for calculating ownership percentages under FCA Disclosure Guidance and Transparency Rules.
- Confirm the remaining capacity under the buyback programme announced on February 24, 2025, given 32 million shares have been purchased to date.
- Review the GSK 2024 Annual Report on Form 20-F for detailed risk factors referenced in the cautionary statement.
- Monitor future Form 6-K filings for subsequent buyback activity under the non-discretionary agreement.